Evidence map›Paper›PMID 28698719›Full record

ArticleStem cells international2017

Long-Term Safety of Transplanting Human Bone Marrow Stromal Cells into the Extravascular Spaces of the Choroid of Rabbits.

Adi Tzameret, Sapir E Kalish, Ifat Sher, Lea Twito, Amilia Meir, Itay Levy, Shlomo Margel, Iris Moroz, Mordechai Rosner, Avraham J Treves and 3 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Adi TzameretMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Sapir E KalishMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Ifat SherMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Lea TwitoMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Amilia MeirCenter for Stem Cells and Regenerative Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Itay LevyDepartment of Chemistry, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Ramat Gan 52900, Israel.ORCID 0000-0002-1689-4032
Shlomo MargelDepartment of Chemistry, Bar-Ilan Institute of Nanotechnology and Advanced Materials, Ramat Gan 52900, Israel.
Iris MorozMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Mordechai RosnerMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0002-8746-0581
Avraham J TrevesCenter for Stem Cells and Regenerative Medicine, Sheba Medical Center, Tel Hashomer, Israel.
Arnon NaglerHematology Division, Sheba Medical Center, Tel Hashomer, Israel.
Michael BelkinMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.
Ygal RotenstreichMaurice and Gabriela Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, Israel.ORCID 0000-0003-0859-3210
Tel Aviv University · ILSheba Medical Center · ILBar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incurable neuroretinal degeneration diseases cause severe vision loss and blindness in millions of patients worldwide. In previous studies, we demonstrated that transplanting human bone marrow stromal cells (hBMSCs) in the extravascular spaces of the choroid (EVSC) of the Royal College of Surgeon rats ameliorated retinal degeneration for up to 5 months. Assessing the safety of hBMSC treatment and graft survival in a large animal is a crucial step before initiating clinical trials. Here, we transplanted hBMSCs into the EVSC compartment of New Zealand White rabbits. No immunosuppressants were used. Transplanted cells were spread across the EVSC covering over 80 percent of the subretinal surface. No cells were detected in the sclera. Cells were retained in the EVSC compartment 10 weeks following transplantation. Spectral domain optical coherence tomography (SD-OCT) and histopathology analysis demonstrated no choroidal hemorrhages, retinal detachment, inflammation, or any untoward pathological reactions in any of transplanted eyes or in the control noninjected contralateral eyes. No reduction in retinal function was recorded by electroretinogram up to 10 weeks following transplantation. This study demonstrates the feasibility and safety of transplanting hBMSCs in the EVSC compartment in a large eye model of rabbits.

Identifiers

PMID28698719
PMCPMC5494107
OpenAlexW2626337003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.